BioLineRx Ltd. (BLRX) Stock Score, Valuation & Financial Research
BioLineRx Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 15/100.
Quick answer for BLRX
BioLineRx Ltd. currently has a Wall Street Score of 15/100. The stored market price is $2.51. Its financial score is 20/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What BioLineRx Ltd. does
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineR
BLRX financial snapshot
- Wall Street Score:
- 15/100
- Current price:
- $2.51
- Market capitalization:
- $10.9M
- Revenue:
- $1.4M
- Net income:
- $-8.0M
- Free cash flow:
- $-8.2M
- Cash:
- $4.6M
- Total debt:
- $7.9M
- EPS:
- -1.82
- Financial score:
- 20/100
- Valuation score:
- 0/100
- Revenue score:
- 17/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-8.2M, showing cash burn in the current stored period.
- The balance sheet shows $4.6M of cash versus $7.9M of total debt, so leverage deserves attention.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 20/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BLRX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.